Home > News > Starpharma Holdings Limited’s VivaGel on the Fast Track to the Market
April 9th, 2007
Starpharma Holdings Limited’s VivaGel on the Fast Track to the Market
Starpharma Holdings Limited (ASX: SPL) makes and develops its products using nanotechnology. Its main drug is called VivaGel, a gel-based microbicide designed to protect women from sexually transmitted diseases, including HIV.
The gel has made it through Phase 1 clinical trials, and the United States Food & Drug Administration (FDA) has even granted the drug fast-track status — and fast-track designation is nothing to scoff at. The term was coined in the FDA Modernization Act of 1997 in an effort to speed up the approval process for some worthy causes. The designation is reserved for new drugs that could address unmet medical needs and treat serious or life-threatening conditions.
New research project supports internationalisation in nano-research: Launch of new “Baltic Sea Network” November 22nd, 2014
Quantum mechanical calculations reveal the hidden states of enzyme active sites November 20th, 2014
Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014
Tokyo Institute of Technology research: Protein-engineered cages aid studies of cell functions November 19th, 2014
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Iranian Experts Clean Uranium-Contaminated Water by Nano-Particles November 23rd, 2014
Novel Method Found for Connection of Metallic Alloys to Polymers November 23rd, 2014
NMTI announces breakthrough solutions for HAMR nanoantenna for next-generation ultra-high density magnetic storage November 21st, 2014
Nano Sorbents Able to Remove Pollutions Caused by Oil Derivatives November 20th, 2014